WORLD HEART FEDERATION (WHF) COVID-19 and Cardiovascular Disease Survey

COVID-19 Clinical Trial

— WHF  

Official title:

WHF COVID-19 and Cardiovascular Disease Survey

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04475471
• Other study ID #: RA1413
• Status: Recruiting
• Start date: September 1, 2020
• Est. completion date: December 31, 2023

Study information

• Verified date: January 2023
• Source: Public Health Foundation of India
• Contact: KAVITA SINGH, PhD
• Phone: 9899691150
• Email: kavita[@]ccdcindia.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A global study for a better understanding of the cardiovascular conditions that increase the risk of developing severe COVID-19, and a better characterization of cardiovascular complications in hospitalized patients with COVID-19.

Description:

COVID-19 may be cardiotropic in a subset of patients. Both acute and pre-existing CVD impact outcomes unfavorably. It is possible that one common CVD treatment, medications that impact ACE-2 function, may impact outcomes either favorably or unfavorably. However, studies so far have, perforce, been conducted with important limitations (e.g. small numbers, limited geographical representation, lack of data standardization for risk factors and outcomes, limited measurement, lack of appropriate adjustment for important confounders, and missing data). Considering the high global prevalence of CVD and its risk factors (e.g. hypertension and diabetes) and the suggested link with COVID19 it is urgent to initiate more robust studies to clarify the many issues early reports have engendered. So that investigators will conduct a global study for a better understanding of the cardiovascular conditions that increase the risk of developing severe COVID-19, and a better characterization of cardiovascular complications in hospitalized patients with COVID-19. Given the continued increase in the COVID-19 cases worldwide, the study team launched WHF COVID-19 and CVD Extension Study to continue recruitment of the COVID-19 patients hospitalized in the selected high-income, middle-income, and low-income countries (sample size = 3300 patients). This extension study will provide valuable insights on the temporal trends in clinical characteristics of COVID-19, the specific cause of deaths such as sudden cardiac death and its relationship with COVID-19 infection, the impact of COVID-19 vaccination on the clinical outcomes at discharge and overall mortality, and anti-microbial resistance and its association with outcomes in COVID-19 patients. Further, the study team is also conducting a WHF COVID-19 Long-term follow-up Study in a sample of 2000 patients from the WHF COVID-19 extension study that aims to determine the short- (3 month), medium- (6 month) and long-term (9-12 month) sequelae to COVID-19 including ongoing symptomatology, re-hospitalizations, mortality, impact on physical function and psycho-social consequences. The long-term sequelae of COVID-19 post hospital discharge are unknown, and the trajectories are likely to be heterogeneous across countries. This study will provide invaluable information about the intermediate to long-term effects of COVID-19 and the disease burden and economic impact of COVID-19 on patients with long term sequelae. Sample Size: 1. WHF COVID-19 and CVD Study (primary cohort): 5200 participants 2. WHF Extension Study: 3300 participants 3. WHF Long term follow-up Study: approx. 2200 participants

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5200
• Est. completion date: December 31, 2023
• Est. primary completion date: December 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All adults (as locally defined) with confirmed COVID-19 infection who are hospitalized are eligible.

Exclusion Criteria:

• Patients for whom investigators are unable to obtain informed consent will be excluded.
• Patients who are unlikely to stay in the recruiting centre for 30 days (i.e. likely to be transferred)

Related Conditions & MeSH terms

• Cardiovascular Diseases
• COVID-19

Locations

Country	Name	City	State
Argentina	Hospital de Clinicas of the University	Buenos Aires
Argentina	Sanatorio Güemes Hospital	Buenos Aires
Bangladesh	Bangladesh Specialized Hospital (BSH)	Dhaka
Bangladesh	Dhaka Medical College Hospital (DMCH)	Dhaka
Bangladesh	DNCC Dedicated COVID-19 Hospital	Dhaka
Bangladesh	Kurmitola General Hospital (KGH)	Dhaka
Bangladesh	Kuwait Bangladesh Friendship Hospital	Dhaka
Bangladesh	Popular Medical College Hospital (PMCH)	Dhaka
Bosnia and Herzegovina	University Clinical Center Republic of Srpska	Srpska
Colombia	Clinica del Occidente, Columbia	Bogotá
Colombia	Fundacion Valle del Lili	Cali
Ghana	Komfo Anokye Teaching Hospital	Kumasi
Ghana	Kumasi South Regional Hospital	Kumasi
India	AIIMS, New Delhi	Delhi
India	Apollo Medical College, Jubilee Hills, Hyderabad, India	Hyderabad
India	Apollol Hopsital,	Hyderabad
India	AIIMS Jodhpur	Jodhpur
India	Dayanand medical college hospital	Ludhiyana	Punjab
Iran, Islamic Republic of	Amin Hospital	Isfahan
Iran, Islamic Republic of	Khorshid Hospital	Isfahan
Japan	Kyoto Medical Center	Kyoto
Japan	National Hospital Organization Kyoto Medical Center, Japan	Kyoto
Kenya	CGTRH-MOMBASA, Kenya	Mombasa
Malaysia	UMMC	Kuala Lumpur
Mexico	ISSSTE Clinica Hospital, Guanajuato	Guanajuato
Nigeria	University College Hospital, Nigeria	Ibadan
Nigeria	Olabisi Onabanjo University Teaching Hospital (OOUTH)	Sagamu
Pakistan	Tabba Heart Institute	Karachi	Sindh
Portugal	University Hospital Sta Maria, Portugal	Lisbon
South Africa	Groote Schuur Hospital, South Africa	Cape Town
Sudan	Fedail Hospital	Khartoum
Zambia	Levy Mwanawasa University Hospital, Zambia	Lusaka

Sponsors (4)

Lead Sponsor	Collaborator
Public Health Foundation of India	Centre for Chronic Disease Control, India, University of Cape Town, World Heart Federation, Geneva, Switzerland

Countries where clinical trial is conducted

Argentina,  Bangladesh,  Bosnia and Herzegovina,  Colombia,  Ghana,  India,  Iran, Islamic Republic of,  Japan,  Kenya,  Malaysia,  Mexico,  Nigeria,  Pakistan,  Portugal,  South Africa,  Sudan,  Zambia, 

References & Publications (28)

Alhogbani T. Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus. Ann Saudi Med. 2016 Jan-Feb;36(1):78-80. doi: 10.5144/0256-4947.2016.78. — View Citation

Alkmim MB, Silva CBG, Figueira RM, Santos DVV, Ribeiro LB, da Paixao MC, Marcolino MS, Paiva JC, Ribeiro AL. Brazilian National Service of Telediagnosis in Electrocardiography. Stud Health Technol Inform. 2019 Aug 21;264:1635-1636. doi: 10.3233/SHTI190571. — View Citation

Alsahafi AJ, Cheng AC. The epidemiology of Middle East respiratory syndrome coronavirus in the Kingdom of Saudi Arabia, 2012-2015. Int J Infect Dis. 2016 Apr;45:1-4. doi: 10.1016/j.ijid.2016.02.004. Epub 2016 Feb 10. — View Citation

Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11. No abstract available. Erratum In: L — View Citation

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28. — View Citation

Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Jul 1;5(7):811-818. doi: 10.1001/jamacardio.2020.1017. Erratum In: JAMA Cardiol. 2020 Jul 1;5(7):848. — View Citation

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum In: Lancet. 2020 Jan 30;: — View Citation

Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, Cani DS, Cerini M, Farina D, Gavazzi E, Maroldi R, Adamo M, Ammirati E, Sinagra G, Lombardi CM, Metra M. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Jul 1;5(7):819-824. doi: 10.1001/jamacardio.2020.1096. — View Citation

Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, Katz K, Ko DT, McGeer AJ, McNally D, Richardson DC, Rosella LC, Simor A, Smieja M, Zahariadis G, Gubbay JB. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med. 2018 Jan 25;378(4):345-353. doi: 10.1056/NEJMoa1702090. — View Citation

Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020 May;109(5):531-538. doi: 10.1007/s00392-020-01626-9. Epub 2020 Mar 11. — View Citation

Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis. 2020 May-Jun;63(3):390-391. doi: 10.1016/j.pcad.2020.03.001. Epub 2020 Mar 10. No abstract available. — View Citation

Madjid M, Miller CC, Zarubaev VV, Marinich IG, Kiselev OI, Lobzin YV, Filippov AE, Casscells SW 3rd. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur Heart J. 2007 May;28(10):1205-10. doi: 10.1093/eurheartj/ehm035. Epub 2007 Apr 17. — View Citation

Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 2020 Jul 1;5(7):831-840. doi: 10.1001/jamacardio.2020.1286. — View Citation

Nguyen JL, Yang W, Ito K, Matte TD, Shaman J, Kinney PL. Seasonal Influenza Infections and Cardiovascular Disease Mortality. JAMA Cardiol. 2016 Jun 1;1(3):274-81. doi: 10.1001/jamacardio.2016.0433. — View Citation

Oudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM, Butany J. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009 Jul;39(7):618-25. doi: 10.1111/j.1365-2362.2009.02153.x. Epub 2009 May 6. — View Citation

Prabhakaran D, Perel P, Roy A, Singh K, Raspail L, Faria-Neto JR, Gidding SS, Ojji D, Hakim F, Newby LK, Stepinska J, Lam CSP, Jobe M, Kraus S, Chuquiure-Valenzuela E, Pineiro D, Khaw KT, Bahiru E, Banerjee A, Narula J, Pinto FJ, Wood DA, Sliwa K. Managem — View Citation

Prabhakaran D, Singh K, Kondal D, Raspail L, Mohan B, Kato T, Sarrafzadegan N, Talukder SH, Akter S, Amin MR, Goma F, Gomez-Mesa J, Ntusi N, Inofomoh F, Deora S, Philippov E, Svarovskaya A, Konradi A, Puentes A, Ogah OS, Stanetic B, Issa A, Thienemann F, — View Citation

Ribeiro AH, Ribeiro MH, Paixao GMM, Oliveira DM, Gomes PR, Canazart JA, Ferreira MPS, Andersson CR, Macfarlane PW, Meira W Jr, Schon TB, Ribeiro ALP. Automatic diagnosis of the 12-lead ECG using a deep neural network. Nat Commun. 2020 Apr 9;11(1):1760. doi: 10.1038/s41467-020-15432-4. Erratum In: Nat Commun. 2020 May 1;11(1):2227. — View Citation

Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H, Yang B, Huang C. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Jul 1;5(7):802-810. doi: 10.1001/jamacardio.2020.0950. — View Citation

Sliwa K, Singh K, Raspail L, Ojji D, Lam CSP, Thienemann F, Ge J, Banerjee A, Newby LK, Ribeiro ALP, Gidding S, Pinto F, Perel P, Prabhakaran D. The World Heart Federation Global Study on COVID-19 and Cardiovascular Disease. Glob Heart. 2021 Apr 19;16(1): — View Citation

Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004 Dec 16;351(25):2611-8. doi: 10.1056/NEJMoa041747. — View Citation

Thienemann F, Chakafana G, Pineiro D, Pinto FJ, Perel P, Singh K, Eisele JL, Prabhakaran D, Sliwa K. WHF Position Statement on COVID Vaccination. Glob Heart. 2021 Apr 27;16(1):29. doi: 10.5334/gh.1027. — View Citation

Thienemann F, Pinto F, Grobbee DE, Boehm M, Bazargani N, Ge J, Sliwa K. World Heart Federation Briefing on Prevention: Coronavirus Disease 2019 (COVID-19) in Low-Income Countries. Glob Heart. 2020 Apr 9;15(1):31. doi: 10.5334/gh.778. — View Citation

Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. — View Citation

Yang C, Jin Z. An Acute Respiratory Infection Runs Into the Most Common Noncommunicable Epidemic-COVID-19 and Cardiovascular Diseases. JAMA Cardiol. 2020 Jul 1;5(7):743-744. doi: 10.1001/jamacardio.2020.0934. No abstract available. — View Citation

Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020 May;94:91-95. doi: 10.1016/j.ijid.2020.03.017. Epub 2020 Mar 12. — View Citation

Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5. — View Citation

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort — View Citation

* Note: There are 28 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of the patients for major adverse cardiovascular events (MACE)	MACE is defined as the presence of any of the following CVD conditions: myocarditis, arrhythmia, heart failure [including Left ventricular ejection fraction], acute coronary event, as per the hospital admission and discharge records. Data will be collected at each site by local investigators and sent to the coordinating center. Only data outlined on the entry and outcome forms will be collected.	Outcome will be assessed at discharge and 30-day follow-up visit from the hospital admission date.
Primary	Assessment of the patients for Pulmonary outcomes including Pulmonary embolism, pneumonia, acute respiratory distress syndrome, need of intensive care - number of days in ICU or ICCU, need of ventilator]	Data will be collected at each site by local investigators and sent to the coordinating center. Only data outlined on the entry and outcome forms will be collected.	at discharge and 30-day follow-up visits from the hospital admission date.
Primary	Assessment of the patients for Neurological Outcomes including stroke and Transient Ischemic Attack (TIA)	Data will be collected at each site by local investigators and sent to the coordinating center. Only data outlined on the entry and outcome forms will be collected.	at discharge and 30-day follow-up visits from the hospital admission date.
Primary	All cause deaths	Specific causes of death to be evaluated using CRF including sudden cardiac death, death due to Myocardial infarction, Death due to heart failure, death due to stroke	any time during the hospital admission and at 30-day follow-up.
Primary	Impact of COVID-19 vaccination on clinical outcomes - MACE (major adverse cardiovascular events) in COVID-19 hospitalized patients.	MACE is defined as the presence of any of the following CVD conditions: myocarditis, arrhythmia, heart failure [including Left ventricular ejection fraction], acute coronary event, as per the hospital admission and discharge records. Data will be collected at each site by local investigators and sent to the coordinating center. Only data outlined on the entry and outcome forms will be collected.	upto 30 days
Primary	Persistence of long-COVID Symptoms at 1-month after discharge among survivors of COVID-19 hospitalizations.	Questionnaires will be administered telephonically at 1-month after hospital discharge. Data will be collected at each site by local investigators and sent to the coordinating center.	1-month after hospital discharge
Primary	Persistence of long-COVID Symptoms at 3-month after discharge among survivors of COVID-19 hospitalizations.	Questionnaires will be administered telephonically at 3-month after hospital discharge. Data will be collected at each site by local investigators and sent to the coordinating center.	3-month after hospital discharge
Primary	Persistence of long-COVID Symptoms at 6-month after discharge among survivors of COVID-19 hospitalizations.	Questionnaires will be administered telephonically at 6-month after hospital discharge. Data will be collected at each site by local investigators and sent to the coordinating center.	6-month after hospital discharge
Primary	Persistence of long-COVID Symptoms at 9-12-month after discharge among survivors of COVID-19 hospitalizations.	Questionnaires will be administered telephonically at 9-12-month after hospital discharge. Data will be collected at each site by local investigators and sent to the coordinating center.	9-12-month after hospital discharge

External Links

•   WHO. Coronavirus disease 2019 (COVID-19) situation report-56